Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial
Abstract Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of hospital-acquired renal impairment in patients undergoing intervention. Limited clinical trials explore SGLT2 inhibitors’ effects on CI-AKI. This study aimed to assess the short-term effect of empagliflozin- an SGLT2 inhi...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-82991-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571764270432256 |
|---|---|
| author | Zeinab Sadat Hosseini Mohammad Javad Jamili Behzad Ensan Ghazaleh Donyadideh Bahram Shahri Hamid Eshraghi Susan Darroudi Mohsen Moohebati |
| author_facet | Zeinab Sadat Hosseini Mohammad Javad Jamili Behzad Ensan Ghazaleh Donyadideh Bahram Shahri Hamid Eshraghi Susan Darroudi Mohsen Moohebati |
| author_sort | Zeinab Sadat Hosseini |
| collection | DOAJ |
| description | Abstract Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of hospital-acquired renal impairment in patients undergoing intervention. Limited clinical trials explore SGLT2 inhibitors’ effects on CI-AKI. This study aimed to assess the short-term effect of empagliflozin- an SGLT2 inhibitor- in reducing CI-AKI incidence in PCI patients regardless of diabetes. This research conducted a double-blind randomized clinical trial involving 121 patients undergoing PCI referred to Ghaem Hospital, Mashhad, Iran from 2022 to 2023. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo, starting one day before PCI and continuing for two days post-procedure. Renal function parameters such as estimated glomerular filtration rate (eGFR), creatinine, cystatin C, and urea were evaluated. After the intervention, empagliflozin users exhibited a significant reduction in mean cystatin C levels compared to the placebo users across all age groups (< 50 years, 50–60 years, and > 60 years). Patients older than 60 showed significant improvements in mean changes of eGFR with empagliflozin. Patients with eGFR > 60 and 45 < eGFR < 60 had a significant increase in eGFR in the empagliflozin group. Mean changes in cystatin C levels were significantly reduced with empagliflozin in all eGFR levels (> 60, 45–60, and < 45). There was no significant difference in urea and creatinine levels between the two groups. Empagliflozin notably decreases CI-AKI incidence in PCI patients by improving renal function parameters such as eGFR and cystatin C. These benefits were observed across various age groups, particularly in middle-aged and elderly, and those with varying renal function levels. |
| format | Article |
| id | doaj-art-f4ba6587ee16463d999dedf5f89fc01c |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-f4ba6587ee16463d999dedf5f89fc01c2025-02-02T12:22:01ZengNature PortfolioScientific Reports2045-23222025-01-0115111110.1038/s41598-024-82991-7Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trialZeinab Sadat Hosseini0Mohammad Javad Jamili1Behzad Ensan2Ghazaleh Donyadideh3Bahram Shahri4Hamid Eshraghi5Susan Darroudi6Mohsen Moohebati7Student Research Committee, Mashhad University of Medical SciencesStudent Research Committee, School of Medicine, Mashhad University of Medical SciencesStudent Research Committee, School of Medicine, Mashhad University of Medical SciencesStudent Research Committee, School of Medicine, Mashhad University of Medical SciencesDepartment of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical SciencesKidney Transplantation Complications Research Center, Mashhad University of Medical SciencesVascular and Endovascular Surgery Research Center, Mashhad University of Medical SciencesDepartment of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical SciencesAbstract Contrast-induced acute kidney injury (CI-AKI) is a prevalent cause of hospital-acquired renal impairment in patients undergoing intervention. Limited clinical trials explore SGLT2 inhibitors’ effects on CI-AKI. This study aimed to assess the short-term effect of empagliflozin- an SGLT2 inhibitor- in reducing CI-AKI incidence in PCI patients regardless of diabetes. This research conducted a double-blind randomized clinical trial involving 121 patients undergoing PCI referred to Ghaem Hospital, Mashhad, Iran from 2022 to 2023. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo, starting one day before PCI and continuing for two days post-procedure. Renal function parameters such as estimated glomerular filtration rate (eGFR), creatinine, cystatin C, and urea were evaluated. After the intervention, empagliflozin users exhibited a significant reduction in mean cystatin C levels compared to the placebo users across all age groups (< 50 years, 50–60 years, and > 60 years). Patients older than 60 showed significant improvements in mean changes of eGFR with empagliflozin. Patients with eGFR > 60 and 45 < eGFR < 60 had a significant increase in eGFR in the empagliflozin group. Mean changes in cystatin C levels were significantly reduced with empagliflozin in all eGFR levels (> 60, 45–60, and < 45). There was no significant difference in urea and creatinine levels between the two groups. Empagliflozin notably decreases CI-AKI incidence in PCI patients by improving renal function parameters such as eGFR and cystatin C. These benefits were observed across various age groups, particularly in middle-aged and elderly, and those with varying renal function levels.https://doi.org/10.1038/s41598-024-82991-7Percutaneous coronary interventionContrast-induced acute kidney injuryEmpagliflozinDiabetes mellitus |
| spellingShingle | Zeinab Sadat Hosseini Mohammad Javad Jamili Behzad Ensan Ghazaleh Donyadideh Bahram Shahri Hamid Eshraghi Susan Darroudi Mohsen Moohebati Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial Scientific Reports Percutaneous coronary intervention Contrast-induced acute kidney injury Empagliflozin Diabetes mellitus |
| title | Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial |
| title_full | Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial |
| title_fullStr | Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial |
| title_full_unstemmed | Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial |
| title_short | Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial |
| title_sort | short term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention a randomised trial |
| topic | Percutaneous coronary intervention Contrast-induced acute kidney injury Empagliflozin Diabetes mellitus |
| url | https://doi.org/10.1038/s41598-024-82991-7 |
| work_keys_str_mv | AT zeinabsadathosseini shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT mohammadjavadjamili shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT behzadensan shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT ghazalehdonyadideh shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT bahramshahri shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT hamideshraghi shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT susandarroudi shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial AT mohsenmoohebati shorttermeffectsofempagliflozinonpreventingcontrastinducedacutekidneyinjuryinpatientsundergoingpercutaneouscoronaryinterventionarandomisedtrial |